Anti-Cancer Drugs // Last Updated: March 11, 2015 .Sanfilippo, Roberta; Dileo, Palma; Blay, Jean-Yves; Constantinidou, Anastasia; Le Cesne, Axel; Benson, Charlotte; Vizzini, Laura; Contu, Marianna; Baldi, Giacomo G.; Dei Tos, Angelo P.; Casali, Paolo G.
Treatment options for patients with metastatic synovial sarcoma are limited. Over recent years, trabectedin has emerged as an effective agent for patients with advanced soft tissue sarcomas resistant to anthracyclines and ifosfamide.
The aim of this retrospective analysis was to study the efficacy of trabectedin in the subgroup of synovial sarcomas.
A retrospective analysis was carried out on patients with advanced synovial sarcoma treated with trabectedin at four European reference sarcoma centers and within the Italian Rare Cancer Network between 2000 and 2013.
Radiological response, progression-free, and overall survival, as well as serious and unexpected adverse events were retrospectively assessed. Sixty-one patients with metastatic synovial sarcoma were identified.
The median number of previous chemotherapy regimens was 2 (range 1-6). Nine patients had a partial response, in addition to two minor responses, and 19 patients had stable disease, for an overall response rate of 15% and a tumor control rate of 50%.
The median progression-free survival was 3 months, with 23% of patients free from progression at 6 months. The median progression-free survival in responding patients was 7 months.
Trabectedin is a therapeutic option for palliative treatment of a subset of patients with metastatic synovial sarcoma.
Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.